Time filter

Source Type

United States

Tabors R.D.,CRA International | Parker G.,Tulane University | Caramanis M.C.,Boston University
Proceedings of the Annual Hawaii International Conference on System Sciences | Year: 2010

This paper seeks to frame one aspect of the Smart Grid discussion which has been under-recognized in regulatory and policy debates. Significant discussion has focused Smart Grid attention on the technologies and on technical interoperability, there has been, we argue, too little attention to questions of the structure or the operation of the market(s) in which the technologies will function. The authors contend that the market structure required for a successful Smart Grid is best understood considering a "platform" framework. We present our view of the interrelationship between that market platform, ultimate customers and power suppliers. It is our conclusion that without a thorough vetting of the market structure within which Smart Grid technologies will function, the full value of the innovations can not be realized. © 2010 IEEE. Source

Rao S.K.,CRA International
Journal of Commercial Biotechnology | Year: 2015

Specialty biologics are the fastest growing class of bio/pharmaceutical products in terms of the number of new brand launches and rates of health care spending in the U.S. and globally. Innovative biologics meant to treat a range of hitherto untreatable conditions in oncology, inflammation, CNS, endocrinology and other chronic conditions seek to offer radical improvements in efficacy and patient well-being. Such products can command premium prices, often costing over $100K per year per patient - triggering a raft of challenges to ensuring that eligible patients have adequate access. This article outlines important trends impacting market access to specialty biologics in the U.S. and globally. Particular importance is placed on evolving methods for managing specialty product utilization and reimbursement toward ensuring appropriate access. The reshaping of the specialty product market access landscape in the U.S. through the availability of oral biologic formulations distributed to patients via high-touch, high-involvement specialty pharmacies is examined. The rising role of risk sharing between specialty product manufacturers and insurers as a way to balance rewards of access with the risks inherent in radical new specialty therapeutics is discussed. Challenges posed by specialty biosimilars to traditional ways of ensuring market access and fair reimbursement are outlined. The impact of health care reforms on market access for specialty biologics in the U.S. is discussed in the context of the growing need for comparative outcomes research and the application of the principles of health technology assessments - adapted, in part from their apparent success in ensuring equitable and cost-effective access to biologics in the E.U. Source

Rao S.K.,CRA International
Journal of Medical Marketing | Year: 2012

There is no dearth of consensus that the global pharmaceutical industry is in the midst of significant change. The search for new drivers of revenue is a strategic imperative. While firms strive to gain efficiencies in how products are discovered, developed and marketed, opportunities exist in redefining the underpinnings of commercial strategies. Of considerable value is the notion of crafting marketing strategy with the patient at the hub. This article discusses elements of a patient-centered commercial strategy, which hold considerable potential in generating revenue growth for a branded drug. The elements are characterized by a strong emphasis on developing practical marketing strategy and ensuing tactics that serve patient needs directly addressable with a commercial brand. Each element is discussed with realworld examples and supported by insights based on original research conducted by the author. Expending intellect, strategic planning and excellence in execution on these elements of commercial strategy will not only shift the locus of a modern bio/pharmaceutical firm toward patients - the customer entity responsible for its existence - it will also serve to replenish flat revenues yearning for more pipeline productivity in the midst of the patent cliff. © The Author(s) 2012. Source

Discover hidden collaborations